Company intelligence / Profile preview

TIXiMED

Birmingham, Alabama, United Statestiximed.com ↗

Ownership: Private
Development stage: Phase 1

Overview

TIXiMED is conducting a first-in-human, single ascending dose Phase 1 trial of its lead candidate, TIX100. The first cohort has been successfully dosed with no significant safety issues reported so far. Preclinical studies demonstrated that TXNIP inhibition protects beta cells and improves islet function in models of type 1 and type 2 diabetes as well as metabolic liver disease[2][4][7].

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecules (specifically, TXNIP inhibitors)
Industry: Biotech

Drug pipeline

1 asset

TIX100

Partnerships

The Leona M. and Harry B. Helmsley Charitable Trust (program-related investment)[4]

Beyond the preview

Go deeper on TIXiMED.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TIXiMED.

Explore the full profile